Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Tianhong Li, MD
University of California, Davis
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Newcastle Private Hospital
New Lambton Heights, New South Wales, Australia
- Tasman Oncology Research
Southport, Queensland, Australia
- Cancer Research Sa
Adelaide, South Australia, Australia
- Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
- Highlands Oncology Group
Springdale, Arkansas, United States
- University of California at Davis
Davis, California, United States
- the Oncology Institute of Hope and Innovation
Downey, California, United States
- City of Hope Cancer Center
Duarte, California, United States
- University of Colorado Hospital
Aurora, Colorado, United States
- Nuvance Health
Norwalk, Connecticut, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Florida Cancer Specialists
Atlantis, Florida, United States
- University of Florida Health Cancer Center
Gainesville, Florida, United States
- Ocala Oncology Florida Cancer Affiliates
Ocala, Florida, United States
- Adventhealth Cancer Institute
Orlando, Florida, United States
- Memorial Cancer Institute
Pembroke Pines, Florida, United States
- Emory University Winship Cancer Institute
Atlanta, Georgia, United States
- Norton Health
Lexington, Kentucky, United States
- Greater Baltimore Medical Center
Baltimore, Maryland, United States
- the Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- University of Michigan Medical Center
Ann Arbor, Michigan, United States
- Atlantic Healthcare System
Morristown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- the Ohio State University James Cancer Center
Columbus, Ohio, United States
- Zangmeister Cancer Center
Columbus, Ohio, United States
- Pennsylvania Cancer Specialists & Research Institute (formerly Gettysburg Cancer Center)
Gettysburg, Pennsylvania, United States
- Prisma Health
Greenville, South Carolina, United States
- Tennessee Oncology Chattanooga Memorial Plaza
Chattanooga, Tennessee, United States
- Tennessee Oncology - Nashville
Nashville, Tennessee, United States
- Houston Methodist Cancer Center
Houston, Texas, United States
- Oncology Consultants
Houston, Texas, United States
- University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States
- Next/virginia Cancer Specialists
Fairfax, Virginia, United States
- University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Sept 2020
- Primary completion
- 30 Jun 2026
- Completion
- 31 Dec 2027
- Last update posted
- 23 May 2025
- Registered enrollment
- 733
- Registry id
- NCT04140526
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.